サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1404639

遺伝子治療の市場規模、シェア、動向分析レポート：適応症別、ベクタータイプ別、地域別、セグメント予測、2024年～2030年

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus, Adenovirus), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 162 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
遺伝子治療の市場規模、シェア、動向分析レポート：適応症別、ベクタータイプ別、地域別、セグメント予測、2024年～2030年
出版日: 2023年11月10日
発行: Grand View Research
ページ情報: 英文 162 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

遺伝子治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の遺伝子治療市場は2023年から2030年にかけて19.5%のCAGRを記録し、2030年までに295億1,000万米ドルに達すると予測されています。

市場開拓の背景には、遺伝子治療に基づく発見件数の増加、この分野への投資の増加、遺伝子治療製品の承認率の上昇があります。WHOによると、2025年までに毎年10～20の新しい細胞療法と遺伝子療法が承認される見込みです。

組換えDNA技術の継続的な開発により、今後数年間は遺伝子治療の効率が高まると予想されています。したがって、遺伝子組換えDNA技術における継続的な進歩は、遺伝子治療の臨床試験数を拡大すると予想されます。主に、このような進歩は、製品の研究開発を強化するための様々な遺伝子編集ツールや発現システムの文脈で起こっています。CRISPR/Cas9ヌクレアーゼ、ZFN、TALENの登場は、簡単かつ正確なゲノム編集を可能にしました。その結果、近年、遺伝子編集分野では多くの研究活動が行われており、遺伝子治療市場の成長にも影響を及ぼすと予想されています。

遺伝子治療市場の成長は、がんの有病率の増加から大きな恩恵を受けると予想されます。年間がん患者数と関連死亡者数の継続的な増加により、強固な治療ソリューションの開発が不可欠であることが強調されています。2020年には、世界中で約1,810万人のがん患者が新たに発生しました。このうち930万人が男性で、880万人が女性です。腫瘍遺伝子研究の継続的な発展は、がんに関連する分子シグネチャーに関する実質的な情報を提供し、ひいてはがん治療薬の進行中の臨床試験をサポートすると期待されています。

強固な疾患治療療法への需要が高まる中、企業はゲノムレベルで疾患の原因を標的とする効果的な遺伝子治療の研究開発を加速させることに注力しています。.さらに米国FDAは、製品製造に関する多くの政策を通じて、この分野のイノベーションを常に支援しています。2020年1月、FDAは安全で効率的な製品の製造と臨床開発に関する6つの最終ガイドラインを発表しました。

さらに、細胞治療や遺伝子治療のための施設拡張は、遺伝子治療市場の成長を促進する主な要因の1つです。遺伝子治療製造のためのいくつかの自社施設やCDMOは、生産能力を強化するための投資を開始しており、その結果、市場プレーヤーにとって有利な機会が生まれると予想されています。例えば、2022年4月、FDAはノバルティスのノースカロライナ州ダーラムの施設の商業認可を承認しました。この認可により、170,000平方フィートの施設は、ゾルゲンマの製造、試験、販売、および現在および今後の臨床試験用の治療製品の製造を許可されました。

遺伝子治療市場レポートハイライト

  • AAVセグメントは2023年に22%の大幅な売上貢献を示します。複数のバイオファーマ企業が、AAVベースの遺伝子治療製品開発のためにウイルスベクタープラットフォームを提供しています。
  • 適応症別では、脊髄性筋萎縮症（SMA）分野が2023年に46.8%のシェアで市場を独占しました。脊髄性筋萎縮症はまれな疾患ではあるが、乳幼児期の致死的な遺伝性疾患としては最も一般的なもの一つです。
  • 予測期間中、最も速いCAGR 38.3%を記録すると予測されるのは、B型サラセミア/SCD分野です。SCDおよびB-サラセミアに対する遺伝子治療は、遺伝子改変造血幹細胞の移植に基づいています。
  • 2023年には北米が65.2％の最大売上シェアで市場を独占しました。この地域は、予測期間中に承認件数と収益で遺伝子治療の最大のルーチン・メーカーになると予想されます。
  • 欧州は、2024年から2030年にかけて最も急成長する地域セグメントと推定されます。これは、アンメット・メディカル・ニーズを抱える人口が多く、希少疾患でありながらますます蔓延している疾患の治療における新規技術への需要が高まっているためです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
  • 市場力学
  • 業界分析ツール

第4章 適応症ビジネス分析

  • 遺伝子治療市場：適応変動分析
  • 急性リンパ性白血病
  • 遺伝性網膜疾患
  • 大細胞型B細胞リンパ腫
  • アデノシンデアミナーゼ（Ada）欠損重度複合免疫不全症（Scid）
  • 黒色腫（病変）
  • ベータサラセミア重度/鎌状赤血球症（Scd）
  • 頭頸部扁平上皮がん
  • 末梢動脈疾患
  • 脊髄性筋萎縮症（SMA）
  • その他

第5章 ベクタータイプビジネス分析

  • 遺伝子治療市場：ベクタータイプの変動分析
  • レンチウイルスベクター
  • アデノ随伴ウイルス（Aav）ベクター
  • レトロウイルスベクター
  • 改変型単純ヘルペスウイルス
  • アデノウイルスベクター
  • 非ウイルスプラスミドベクター
  • その他

第6章 地域ビジネス分析

  • 地域別の遺伝子治療市場シェア、2023年と2030年
  • 北米
    • 北米遺伝子治療市場、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の遺伝子治療市場、2018年から2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋地域
    • アジア太平洋地域の遺伝子治療市場、2018年から2030年
    • 日本
    • 中国
    • オーストラリア
  • 世界のその他の地域
    • 世界のその他の地域の遺伝子治療市場、2018～2030年

第7章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市場シェア分析、2023年
  • 企業プロファイル
    • REGENXBIO, INC
    • OXFORD BIOMEDICA PLC
    • VOYAGER THERAPEUTICS
    • HUMAN STEM CELLS INSTITUTE
    • DIMENSION THERAPEUTICS, INC
    • BRISTOL-MYERS SQUIBB COMPANY
    • SANOFI
    • APPLIED GENETIC TECHNOLOGIES CORPORATION
    • F. HOFFMANN-LA ROCHE LTD
    • BLUEBIRD BIO, INC
    • NOVARTIS AG
    • TAXUS CARDIUM PHARMACEUTICALS GROUP, INC.（GENE BIOTHERAPEUTICS）
    • UNIQURE NV
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • CELLECTIS SA
    • SANGAMO THERAPEUTICS, INC.
    • ORCHARD THERAPEUTICS
    • GILEAD LIFESCIENCES, INC.
    • BENITEC BIOPHARMA
    • SIBIONO GENETECH CO., LTD
    • SHANGHAI SUNWAY BIOTECH CO., LTD.
    • GENSIGHT BIOLOGICS SA
    • TRANSGENE
    • CALIMMUNE, INC
    • EPEIUS BIOTECHNOLOGIES CORP.
    • ASTELLAS PHARMA INC
    • AMERICAN GENE TECHNOLOGIES
    • BIOMARIN PHARMACEUTICALS, INC
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Tables
  • Table 3 List of Secondary Sources
  • Table 4 List of Abbreviations
  • Table 5 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 6 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 7 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 10 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 13 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 15 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 18 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 19 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 20 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 21 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 22 France Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 23 France Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 24 Italy Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 26 Spain Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 31 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 32 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 33 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 34 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 35 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 36 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 37 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 38 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 39 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 40 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Gene Therapy Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 Penetration & Growth Prospect Mapping
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
  • Fig. 15 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
  • Fig. 17 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
  • Fig. 18 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
  • Fig. 19 Global Gene Therapy Market for Non-viral Plasmid Vector, 2018 - 2030 (USD Million)
  • Fig. 20 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
  • Fig. 21 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
  • Fig. 22 Global Acute Lymphoblastic Leukemia (ALL) patients treated with gene therapy, 2018 - 2030
  • Fig. 23 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
  • Fig. 24 Global Inherited Retinal Disease patients treated with gene therapy, 2018 - 2030
  • Fig. 25 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 26 Global Large B-cell Lymphoma patients treated with gene therapy, 2018 - 2030
  • Fig. 27 Global Gene Therapy Market for ADA-SCID, 2018 - 2030 (USD Million)
  • Fig. 28 Global ADA-SCID patients treated with gene therapy, 2018 - 2030
  • Fig. 29 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
  • Fig. 30 Global Melanoma (lesions) patients treated with gene therapy, 2018 - 2030
  • Fig. 31 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
  • Fig. 32 Global Beta-Thalassemia Major/SCD patients treated with gene therapy, 2018 - 2030
  • Fig. 33 Global Gene Therapy Market for Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
  • Fig. 34 Global Head & Neck Squamous Cell Carcinoma patients treated with gene therapy, 2018 - 2030
  • Fig. 35 Global Gene Therapy Market for Peripheral arterial disease, 2018 - 2030 (USD Million)
  • Fig. 36 Global Peripheral arterial disease patients treated with gene therapy, 2018 - 2030
  • Fig. 37 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
  • Fig. 38 Global Spinal Muscular Atrophy (SMA) patients treated with gene therapy, 2018 - 2030
  • Fig. 39 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Global Other diseases patient treated with gene therapy, 2018 - 2030
  • Fig. 41 Regional Outlook, 2022 & 2030
  • Fig. 42 North America Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 44 Canada Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 45 Europe Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 46 Germany Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 47 UK Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 48 France Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 49 Italy Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 50 Spain Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 52 Japan Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 53 China Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 54 Australia Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 55 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 56 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-179-5

Gene Therapy Market Growth & Trends:

The global gene therapy market is expected to reach USD 29.51 billion by 2030, registering a CAGR of 19.5% from 2023 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights:

  • The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
  • By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
  • The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and B-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
  • North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
  • Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Application & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Application & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Robust Gene Therapy Pipeline
      • 3.2.1.2. Introduction Of Technological Advancements
      • 3.2.1.3. Increasing Investment From Companies And Partnerships
      • 3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Absence Of Effective Diagnosis Framework
      • 3.2.2.2. High Prices Of Gene Therapy
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
      • 3.2.3.2. Facility Expansion For Cell And Gene Therapies
      • 3.2.3.3. Technological Advancements In Manufacturing Vectors
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Indication Business Analysis

  • 4.1. Gene Therapy Market: Indication Movement Analysis
  • 4.2. Acute Lymphoblastic Leukemia
    • 4.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.3. Inherited Retinal Disease
    • 4.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
  • 4.4. Large B-Cell Lymphoma
    • 4.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.5. Adenosine Deaminase (Ada)-Deficient Severe Combined Immunodeficiency (Scid)
    • 4.5.1. Adenosine Deaminase (Ada)-Deficient Severe Combined Immunodeficiency (Scid) Market, 2018 - 2030 (USD Million)
  • 4.6. Melanoma (lesions)
    • 4.6.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
  • 4.7. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
    • 4.7.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
  • 4.8. Head & Neck Squamous Cell Carcinoma
    • 4.8.1. Head & Neck Squamous Cell Carcinoma Market, 2018 - 2030 (USD Million)
  • 4.9. Peripheral arterial disease
    • 4.9.1. Peripheral arterial disease Market, 2018 - 2030 (USD Million)
  • 4.10. Spinal Muscular Atrophy (SMA)
    • 4.10.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vector Type Business Analysis

  • 5.1. Gene Therapy Market: Vector Type Movement Analysis
  • 5.2. Lentiviral Vectors
    • 5.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
  • 5.3. Adeno-Associated Viral (Aav) Vectors
    • 5.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
  • 5.4. Retrovirus Vectors
    • 5.4.1. Retrovirus Vectors market, 2018 - 2030 (USD Million)
  • 5.5. Modified Herpes Simplex Virus
    • 5.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
  • 5.6. Adenovirus Vectors
    • 5.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
  • 5.7. Non-Viral Plasmid Vector
    • 5.7.1. Non-Viral Plasmid Vector market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Gene Therapy Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target disease prevalence
      • 6.2.2.3. Competitive Scenario
      • 6.2.2.4. Regulatory Framework
      • 6.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target disease prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target disease prevalence
      • 6.3.2.3. Competitive Scenario
      • 6.3.2.4. Regulatory Framework
      • 6.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target disease prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target disease prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. France Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target disease prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Italy Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target disease prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Spain Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target disease prevalence
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Regulatory Framework
      • 6.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target disease prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.4. Australia
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target disease prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.5. Rest of the world
    • 6.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. REGENXBIO, INC
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. OXFORD BIOMEDICA PLC
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. VOYAGER THERAPEUTICS
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. HUMAN STEM CELLS INSTITUTE
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. DIMENSION THERAPEUTICS, INC
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. BRISTOL-MYERS SQUIBB COMPANY
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. SANOFI
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. APPLIED GENETIC TECHNOLOGIES CORPORATION
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. F. HOFFMANN-LA ROCHE LTD
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. BLUEBIRD BIO, INC
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. NOVARTIS AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives
    • 7.4.13. UNIQURE N.V.
      • 7.4.13.1. Overview
      • 7.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.13.3. Product Benchmarking
      • 7.4.13.4. Strategic Initiatives
    • 7.4.14. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 7.4.14.1. Overview
      • 7.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.14.3. Product Benchmarking
      • 7.4.14.4. Strategic Initiatives
    • 7.4.15. CELLECTIS S.A.
      • 7.4.15.1. Overview
      • 7.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.15.3. Product Benchmarking
      • 7.4.15.4. Strategic Initiatives
    • 7.4.16. SANGAMO THERAPEUTICS, INC.
      • 7.4.16.1. Overview
      • 7.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.16.3. Product Benchmarking
      • 7.4.16.4. Strategic Initiatives
    • 7.4.17. ORCHARD THERAPEUTICS
      • 7.4.17.1. Overview
      • 7.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.17.3. Product Benchmarking
      • 7.4.17.4. Strategic Initiatives
    • 7.4.18. GILEAD LIFESCIENCES, INC.
      • 7.4.18.1. Overview
      • 7.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.18.3. Product Benchmarking
      • 7.4.18.4. Strategic Initiatives
    • 7.4.19. BENITEC BIOPHARMA
      • 7.4.19.1. Overview
      • 7.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.19.3. Product Benchmarking
      • 7.4.19.4. Strategic Initiatives
    • 7.4.20. SIBIONO GENETECH CO., LTD
      • 7.4.20.1. Overview
      • 7.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.20.3. Product Benchmarking
      • 7.4.20.4. Strategic Initiatives
    • 7.4.21. SHANGHAI SUNWAY BIOTECH CO., LTD.
      • 7.4.21.1. Overview
      • 7.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.21.3. Product Benchmarking
      • 7.4.21.4. Strategic Initiatives
    • 7.4.22. GENSIGHT BIOLOGICS S.A.
      • 7.4.22.1. Overview
      • 7.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.22.3. Product Benchmarking
      • 7.4.22.4. Strategic Initiatives
    • 7.4.23. TRANSGENE
      • 7.4.23.1. Overview
      • 7.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.23.3. Product Benchmarking
      • 7.4.23.4. Strategic Initiatives
    • 7.4.24. CALIMMUNE, INC
      • 7.4.24.1. Overview
      • 7.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.24.3. Product Benchmarking
      • 7.4.24.4. Strategic Initiatives
    • 7.4.25. EPEIUS BIOTECHNOLOGIES CORP.
      • 7.4.25.1. Overview
      • 7.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.25.3. Product Benchmarking
      • 7.4.25.4. Strategic Initiatives
    • 7.4.26. ASTELLAS PHARMA INC
      • 7.4.26.1. Overview
      • 7.4.26.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.26.3. Product Benchmarking
      • 7.4.26.4. Strategic Initiatives
    • 7.4.27. AMERICAN GENE TECHNOLOGIES
      • 7.4.27.1. Overview
      • 7.4.27.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.27.3. Product Benchmarking
      • 7.4.27.4. Strategic Initiatives
    • 7.4.28. BIOMARIN PHARMACEUTICALS, INC
      • 7.4.28.1. Overview
      • 7.4.28.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.28.3. Product Benchmarking
      • 7.4.28.4. Strategic Initiatives